Abstract
Patients with cirrhosis are at a risk for developing HCC. MRI and other radiologic imaging methods are often able to diagnose HCC in high-risk populations often before elevation in serum alpha-fetoprotein and other nonimaging signs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Snowberger N, Chinnakotla S, Lepe RM, et al. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther. 2007;26:1187–94.
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.
Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97–104 (Erratum in: Hepatology 2008; 47:769).
Ohtomo K, Baron RL, Dodd GD, Federle MP, Ohtomo Y, Confer SR. Confluent hepatic fibrosis in advanced cirrhosis: evaluation with MR imaging. Radiology. 1993;189:871–4.
Wanless IR, et al. Terminology of nodular hepatocellular lesions. International working party. Hepatology. 1995;22:983–93.
Krnisky GA, Lee VS, Theise ND, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology. 2001;219:445–54.
Quaia E, De Paoli L, Pizzolato R, Angileri R, Pantano E, Degrassi F, Ukmar M, Cova MA. Predictors of dysplastic nodule diagnosis in patients with liver cirrhosis on unenhanced and gadobenate dimeglumine-enhanced MRI with dynamic and hepatobiliary phase. Am J Roentgenol. 2013;200(3):553–62.
Serste T, Barrou V, Ozenne V, Vullierme MP, Bedossa P, Farges O, et al. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology. 2012;55:800–6.
Kim TK, Lee KH, Jang JH, Haider MA, Jacks LM, Menezes RJ, et al. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1–2 cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology. 2011;259:730–8.
Sangiovanni A, Manini MA, Iavoarone M, Romeo R, Forzenigo LV, Fraquelli M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut. 2010;59:638–44.
Loni S, Piscaglia F, Folfieri R, Camaggi V, Vidilli G, Pini P, Bolondi L. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol. 2010;105:599–609.
Jang HJ, Kim TK, Khalili K, Yazdi L, Menezes R, Park SH, Sherman M. Characterization of 1–2 cm liver nodules detected on HCC surveillance ultrasound according to the criteria of the American Association for the Study of Liver Disease: is quadriphasic CT necessary? Am J Roentgenol. 2013;201:314–21.
American College of Radiology. Liver Imaging Reporting and Data System version 2014. http://www.acr.org/Quality-Safety/Resources/LIRADS. Accessed August 2014.
OPTN policy management. http://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf#nameddest=Policy_09. Accessed 4 August 2015.
Prasad SR, Wang H, et al. Fat-containing lesions of the liver: radiologic-pathologic correlation. Radiographics. 2005;25(2):321–31.
Yoshioka H, Takahashi N, Yamaguchi M, et al. Double arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinomas. J Magn Reson Imaging. 2002;16:259–66.
Chou C-T, Chou J-M, Chang T-A, et al. Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging. World J Gastroenterol: WJG. 2013;19(42):7433–9. doi:10.3748/wjg.v19.i42.7433.
Kim YK, et al. Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial? Clin Radiol. 2011;66(6):489–96.
Vandecaveye V, et al. Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol. 2009;19(10):2456–66.
Xu PJ, et al. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis. J Magn Reson Imaging. 2009;29(2):341–9.
Yu JS, et al. Detection of small intrahepatic metastases of hepatocellular carcinomas using diffusion-weighted imaging: comparison with conventional dynamic MRI. Magn Reson Imaging. 2011;29(7):985–92.
Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics. 2009;20:1725–48.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Patel, A., Malhotra, N., Roth, C.G., Deshmukh, S., Mitchell, D.G. (2016). MRI for Detection and Evaluation of Hepatocellular Carcinoma. In: Carr, B. (eds) Hepatocellular Carcinoma. Current Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-34214-6_25
Download citation
DOI: https://doi.org/10.1007/978-3-319-34214-6_25
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-34212-2
Online ISBN: 978-3-319-34214-6
eBook Packages: MedicineMedicine (R0)